Dashboard
Manage Tickers

LGND


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ligand-partner-travere-therapeutics-receives-full-fda-approval-for-filspari
Ligand Partner Travere Therapeutics Receiv...
09/06/2024 13:23:17

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; upda...

looking-into-ligand-pharmaceuticalss-recent-short-interest
Looking Into Ligand Pharmaceuticals's Rece...
08/16/2024 13:00:21

benchmark-maintains-buy-on-ligand-pharmaceuticals-raises-price-target-to-110
Benchmark Maintains Buy on Ligand Pharmace...
08/12/2024 16:53:08

Benchmark analyst Robert Wasserman maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target fro...

rbc-capital-reiterates-outperform-on-ligand-pharmaceuticals-maintains-130-price-target
RBC Capital Reiterates Outperform on Ligan...
08/12/2024 16:28:30

RBC Capital analyst Douglas Miehm reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and maintains $130 price...

hc-wainwright--co-reiterates-buy-on-ligand-pharmaceuticals-maintains-144-price-target
HC Wainwright & Co. Reiterates Buy on Liga...
08/08/2024 10:48:42

HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $1...

rbc-capital-reiterates-outperform-on-ligand-pharmaceuticals-maintains-130-price-target
RBC Capital Reiterates Outperform on Ligan...
08/07/2024 17:13:53

RBC Capital analyst Douglas Miehm reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and maintains $130 price...

ligand-sees-2024-core-adj-eps-500-550-vs-516-est-sees-total-revenue-140m-157m-vs-14717m-est
Ligand Sees 2024 Core Adj. EPS $5.00-$5.50...
08/06/2024 20:49:38

ligand-pharmaceuticals-q2-2024-adj-eps-140-beats-106-estimate-sales-41531m-beat-32865m-estimate
Ligand Pharmaceuticals Q2 2024 Adj. EPS $1...
08/06/2024 20:27:38

Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate o...

assessing-ligand-pharmaceuticals-insights-from-6-financial-analysts
Assessing Ligand Pharmaceuticals: Insights...
07/30/2024 12:01:10

rbc-capital-initiates-coverage-on-ligand-pharmaceuticals-with-outperform-rating-announces-price-target-of-130
RBC Capital Initiates Coverage On Ligand P...
07/30/2024 10:03:05

RBC Capital analyst Douglas Miehm initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform rating and an...

craig-hallum-maintains-buy-on-ligand-pharmaceuticals-raises-price-target-to-140
Craig-Hallum Maintains Buy on Ligand Pharm...
07/09/2024 17:27:38

Craig-Hallum analyst Matt Hewitt maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from ...

hc-wainwright--co-reiterates-buy-on-ligand-pharmaceuticals-maintains-144-price-target
HC Wainwright & Co. Reiterates Buy on Liga...
07/08/2024 17:58:16

HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $1...

ligand-pharma-to-acquire-apeiron-biologics-ag-for-100m-expects-2024-revenue-of-140m-157m-prior-130m-142m-vs-13779m-est-2024-adj-eps-of-500-550-prior-425-475-vs-464-est
Ligand Pharma to Acquire APEIRON Biologics...
07/08/2024 11:08:27

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it has entered into a definitive agreement to acquire AP...

what-4-analyst-ratings-have-to-say-about-ligand-pharmaceuticals
What 4 Analyst Ratings Have To Say About L...
06/28/2024 19:01:14

benchmark-reiterates-buy-on-ligand-pharmaceuticals-maintains-95-price-target
Benchmark Reiterates Buy on Ligand Pharmac...
06/28/2024 14:15:22

Benchmark analyst Robert Wasserman reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $95 price target.

hc-wainwright--co-reiterates-buy-on-ligand-pharmaceuticals-maintains-144-price-target
HC Wainwright & Co. Reiterates Buy on Liga...
06/27/2024 15:46:31

HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $1...

ligand-pharmaceuticals-announces-fda-approval-of-ohtuvayre-increasing-commercial-stage-portfolio-to-11-products-earns-58m-milestone-payment-and-anticipates-138m-upon-commercial-launch-entitled-to-low-single-digit-royalty-on-global-sales-of-copd-treatment
Ligand Pharmaceuticals Announces FDA Appro...
06/27/2024 12:04:10

Core News & Articles
FDA Approves CAPVAXIVE, Sixth Product Usin...
06/18/2024 12:03:40

hc-wainwright--co-reiterates-buy-on-ligand-pharmaceuticals-maintains-144-price-target
HC Wainwright & Co. Reiterates Buy on Liga...
05/08/2024 10:33:15

HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $1...

ligand-pharmaceuticals-reaffirms-fy24-adj-eps-425-475-vs-444-est-revenue-130m-142m-vs-137680m-est
Ligand Pharmaceuticals Reaffirms FY24 Adj....
05/07/2024 21:23:45

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION